Skip to main content

Table 7 The associations between the relevant clinic-pathological features of stage II CRC patients and disease free survival

From: Aberrant expression of miRNAs predicts recurrence and survival in stage-II colorectal cancer patients from Egypt

Factors N = 124 (%) Disease free survival % Median months (95% CI) Log rankP value
1 yr 2 yrs 3 yrs 5 yrs 10 yrs
All 124 (100) 81.2 67.4 62.1 60.2 45.6 72.0 NA
Age (yrs)
 ≤ 45 60 (48.4) 81.3 69.4 64.2 64.2 40.1 66 (52-79) 0.917
 > 45 64 (51.6) 81.1 65.4 60.3 55.4 47.7 103
Gender
 Male 64 (51.6) 76.2 63.0 60.3 60.3 41.4 72 (4-139) 0.41
 Female 60 (48.4) 86.4 72.1 63.8 59.3 51.9 NA
Residence
 Urban 66 (53.2) 86.0 71.3 64.5 64.5 54.5 NA 0.225
 Rural 58 (48.4) 81.0 63.0 59.9 55.3 NA 62 (21-102)
DM
 - ve 109 (87.9) 81.3 67.5 64.4 62.3 47.2 103 0.414
 + ve 15 (12.1) 80.0 66.7 44.4 NA NA 30 (21-38)
HTN
 - ve 110 (88.7) 81.7 67.1 61.1 58.9 41.9 72 (14.8-129.1) 0.434
 + ve 14 (11.3) 76.9 69.2 69.2 69.2 69.2 NA
Family history
 - ve 103 (83.1) 79.2 65.9 61.3 59.0 44.6 103 (28.2-177.5) 0.804
 + ve 21 (16.9) 90.5 73.5 65.3 65.3 49.0 NA
Smoking
 - ve 88 (71) 94.4 75.6 73.4 70.2 53.0 NA 0.078
 + ve 36 (29) 74.3 57.0 52.6 52.6 39.5 103 (0-225)
PS
 0 56 (45.2) 89.3 81.7 79.2 75.5 51.0 NA 0.016
 I 48 (38.7) 76.6 56.6 49.0 49.0 49.0 32
 II 20 (16.1) 68.6 52.3 43.5 43.5 NA 30 (8.1-51.9)
Pathology
 Adenocarcinoma 105 (84.7) 82.5 68.5 62.3 60.2 47.5 72 0.713
 Mucinous 19 (15.3) 73.7 61.4 61.4 61.4 40.6 103 (0-249)
Grade
 I-II 109 (87.9) 81.3 68.7 64.2 62.1 46.4 102 0.425
 III 15 (12.1) 80.0 58.7 46.9 46.9 NA 32
T. stage
 T3 84 (67.7) 85.4 76.7 69.5 66.8 45.9 103 0.058
 T4 40 (32.3) 75.0 46.0 46.0 46.0 46.0 21
Dissected LN
 < 12 60 (48.4) 81.7 69.5 64.5 60.9 44.3 66 (49.7-82.2) 0.89
 ≥ 12 64 (51.6) 80.7 65.4 60.2 60.2 48.1 103
Adjuvant
 No 30 (24.2) 88.6 70.8 61.0 54.2 54.2 NA 0.787
 Yes 94 (75.8) 79.4 66.4 61.1 61.1 43.4 72 (25.3-118.7)
  1. The data in boldface denotes the presence of statistically significant difference between the studied groups